Molecular Analysis of IgE Antibodies in Walnut Allergic Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02295267

Enrollment

Registered

2014-11-20

Start date

2012-12-31

Completion date

2017-03-31

Last updated

2017-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergy

Keywords

Food allergy, Walnut, Components, Allergens

Brief summary

Accurate diagnosis of food allergy depends on the identification of the causative allergenic molecule(s). The proposed study intends to investigate and compare the pattern of IgE antibody sensitisation in walnut allergic subjects from three different regions of Europe (south (SEU) and central/north (C/NEU), to evaluate the diagnostic utility of a panel of novel allergen reagents.

Detailed description

Accurate diagnosis of food allergy depends on the identification of the causative allergenic molecule(s). Thus, full characterization of the major allergens of walnut and their clinical importance is an important undertaking. The proposed study intends to investigate and compare the pattern of IgE antibody sensitisation in walnut allergic subjects from three different regions of Europe (south (SEU) and central/north (C/NEU), to evaluate the diagnostic utility of a panel of novel allergen reagents. With a view towards improved in vitro diagnostic methods, we intend to evaluate the diagnostic potential of recombinant walnut allergens in patients with walnut allergy confirmed by a positive provocation or supported by a convincing history of anaphylactic reaction(s) to walnut in the past, patients with pollinosis but no symptoms of walnut allergy and non-atopic control subjects.

Interventions

OTHERwalnut allergy provocation

double blind placebo controlled food challenge

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

1 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Signed informed consent * Group A: positive case history of allergic reaction(s) to walnut * Group B: positive case history of allergy to birch, grass or olive pollen and no case history of allergic reaction(s) to walnut * Group C: no case history of atopic disease

Exclusion criteria

* Known pregnancy * Breast-feeding of infant * Treatment with the following drugs (or shortest interval between last treatment and food challenge or SPT): * corticosteroids (2 weeks): applied systemically, to the nose or locally on the skin test area. * antihistamines (3 days) except hydroxyzine (10 days) * betablocker agents (1 day) * angiotensin converting enzyme inhibitors (2 days) * Any major organic or infectious disease

Design outcomes

Primary

Measure	Time frame
numbers of patients with walnut allergy	December 2012 to November 2017, up to 5 years

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026